Abstract
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, generically termed statins, are widely prescribed for their cholesterol-lowering properties. In addition to lipid-lowering properties, statins have pleiotropic effects including anti-inflammatory, anti-apoptotic, and antiproliferative effects. Recently, data from experimental and observational studies have indicated that statins could also become a treatment option for diseases of the central nervous system (CNS). Many neurodegenerative diseases particularly affect the retina and other ocular structures and are the cause for blindness. This review, focused on recent clinical and experimental data, discusses known and putative mechanisms of statin actions underlying neuroprotective effects in relevant retinal and eye diseases. In addition, it presents evidence for the role of heat shock proteins (Hsps) as target of statin-mediated neuroprotective effects in ocular diseases.
Keywords: Statin, retina, eye diseases, neuroprotection, cholesterol, isoprenylation
CNS & Neurological Disorders - Drug Targets
Title: Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
Volume: 6 Issue: 4
Author(s): Christian Schmeer, Alexandra Kretz and Stefan Isenmann
Affiliation:
Keywords: Statin, retina, eye diseases, neuroprotection, cholesterol, isoprenylation
Abstract: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, generically termed statins, are widely prescribed for their cholesterol-lowering properties. In addition to lipid-lowering properties, statins have pleiotropic effects including anti-inflammatory, anti-apoptotic, and antiproliferative effects. Recently, data from experimental and observational studies have indicated that statins could also become a treatment option for diseases of the central nervous system (CNS). Many neurodegenerative diseases particularly affect the retina and other ocular structures and are the cause for blindness. This review, focused on recent clinical and experimental data, discusses known and putative mechanisms of statin actions underlying neuroprotective effects in relevant retinal and eye diseases. In addition, it presents evidence for the role of heat shock proteins (Hsps) as target of statin-mediated neuroprotective effects in ocular diseases.
Export Options
About this article
Cite this article as:
Christian Schmeer , Alexandra Kretz and Stefan Isenmann , Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases, CNS & Neurological Disorders - Drug Targets 2007; 6 (4) . https://dx.doi.org/10.2174/187152707781387260
DOI https://dx.doi.org/10.2174/187152707781387260 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Patent Selections:
Recent Patents on Regenerative Medicine Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews The Roles of MicroRNAs in Heart Diseases: A Novel Important Regulator
Current Medicinal Chemistry Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Synthesis and <i>In Vitro</i> Cytotoxic Evaluation of Novel Murrayafoline A Derived β-Amino Alcohols
Letters in Organic Chemistry Adequacy of Quality Assurance Programs for a Corn Meal Production Unit
The Natural Products Journal Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Flavonoids Isolated from Rumex aquaticus Exhibit Neuroprotective and Neurorestorative Properties by Enhancing Neurite Outgrowth and Synaptophysin
CNS & Neurological Disorders - Drug Targets The Gut Microbiota and Lipid Metabolism: Implications for Human Health and Coronary Heart Disease
Current Medicinal Chemistry